Tilfrinib is primarily utilized in the field of oncology as a targeted therapy for certain types of cancers. It functions as a kinase inhibitor, specifically targeting and inhibiting the activity of particular enzymes involved in cancer cell growth and proliferation. By blocking these enzymes, Tilfrinib helps to slow down or halt the progression of cancer, making it a valuable component in treatment regimens for patients with specific genetic mutations or cancer types. Its application is often seen in cases where traditional chemotherapy or other treatments have proven less effective, offering a more personalized approach to cancer management. Additionally, ongoing research explores its potential in combination therapies to enhance overall treatment efficacy and patient outcomes.